Search
This Journal
Anywhere
Quick Search in Journals
Enter words / phrases / DOI / ISBN / keywords / authors / etc
Quick Search anywhere
Enter words / phrases / DOI / ISBN / keywords / authors / etc
Advanced Search
0 My Cart
Sign in
Institutional Access

Meta-AnalysisOpen Access cc icon

Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis

Kendra DeBusk

,

Shaun Abeysinghe

,

Adrian Vickers

,

Anubhav Nangia

,

Judith Bell

,

Chiemeka Ike

,

Andres Forero-Torres

&

Matthew T Blahna

*Author for correspondence:

E-mail Address: kdebusk@seagen.com

Global Health Economics Outcome Research, Seagen Inc., Bothell, WA 98021, USA

Search for more papers by this author

,

Shaun Abeysinghe

https://orcid.org/0000-0003-0522-5842

RTI Health Solutions, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK

Search for more papers by this author

,

https://orcid.org/0000-0003-0304-1951

RTI Health Solutions, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK

Search for more papers by this author

,

https://orcid.org/0000-0002-9974-5779

RTI Health Solutions, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK

Search for more papers by this author

,

https://orcid.org/0000-0002-9651-7463

RTI Health Solutions, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK

Search for more papers by this author

,

https://orcid.org/0000-0001-6309-6458

Global Health Economics Outcome Research, Seagen Inc., Bothell, WA 98021, USA

Search for more papers by this author

,

Andres Forero-Torres

https://orcid.org/0000-0001-5161-8319

Global Clinical Development, Seagen Inc., Bothell, WA 98021, USA

Search for more papers by this author

&

Matthew T Blahna

https://orcid.org/0000-0001-9857-902X

Global Medical Affairs, Seagen Inc., Bothell, WA 98021, USA

Search for more papers by this author

Published Online:31 Aug 2021https://doi.org/10.2217/fon-2021-0742

Supplemental Material

supplementary figures.docx (2 MB)

supplementary tables.docx (58 KB)

supplementary_figure_1.eps (1 MB)

supplementary_figure_2_a-d.pdf (920 KB)

supplementary_figure_3_a-b.eps (1 MB)

Vol. 17, No. 33

Supplemental Materials

Metrics

Downloaded 4,446 times

History

Received 15 June 2021

Accepted 6 August 2021

Published online 31 August 2021

Published in print November 2021

Information

© 2021 Kendra DeBusk

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2021-0742

Financial & competing interests disclosure

This study was sponsored by Seagen Inc. K DeBusk, C Ike, A Forero-Torres and MT Blahna are employees and stockholders of Seagen Inc. S Abeysinghe, A Vickers, A Nangia and J Bell are employees of RTI Health Solutions, which received funding from Seagen Inc. for the analyses reported in this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Medical writing assistance was provided by M Bell of Curo (part of Envision Pharma Group), and was funded by Seagen Inc.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/